Picture of Biofrontera AG logo

B8F Biofrontera AG Share Price

0.000.00%
de flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSuper Stock

Momentum

Relative Strength (%)
1m-7.19%
3m+7.73%
6m+33.17%
1yr-8.28%
Volume Change (%)
10d/3m-46.42%
Price vs... (%)
52w High-7.8%
50d MA+1.2%
200d MA+21.68%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital233.4%
Return on Equity69.45%
Operating Margin127.98%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Biofrontera AG EPS forecast chart

Profile Summary

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.

Directors

Last Annual
December 31st, 2021
Last Interim
September 30th, 2022
Incorporated
November 16th, 2000
Public Since
October 30th, 2006
No. of Employees
102
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
de flag iconXETRA
Shares in Issue
63,807,058
Blurred out image of a map
Address
Hemmelrather Weg 201, LEVERKUSEN, 51377
Web
https://biofrontera.com/
Phone
+49 null214876320
Contact
Tirth Patel
Auditors
Warth & Klein Grant Thornton AG

B8F Share Price Performance

FAQ

Or unlock with your email

Or unlock with your email